Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CD22 CAR-T cells (Institute of Hematology & Blood Diseases Hospital)
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational bispecific CAR-T cell therapy developed by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. The therapy is designed to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) by engineering autologous T-cells to express a chimeric antigen receptor (CAR) that simultaneously targets both CD19 and CD22 antigens. The CAR construct utilizes scFvs derived from hybridoma clones HIB22 and HI19a, linked with a CD8α signal peptide and transmembrane domain, a 4-1BB costimulatory domain, and a CD3ζ cytoplasmic signaling region. This dual-targeting strategy is intended to overcome antigen escape and reduce relapse rates associated with single-target CD19 CAR-T therapies.
- Other names
- bispecific CD19-CD22 CAR-T cellstandem CD19-CD22 CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD19-CD22 CAR-T cells (Institute of Hematology & Blood Diseases Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CD22 CAR-T cells (Institute of Hematology & Blood Diseases Hospital).